Slide 1: Q2 presentation
vimian’ Q2 presentation July 2025
Slide 2: Introductory remarks from the Chairman of the Board
Introductory remarks from the Chairman of the Board / Leadership changes to drive long-term success implemented – strong interim solution in place / Continuing to execute a robust strategy of profitable organic and acquisition driven growth / Board is confident in Vimian’s ability to deliver on full
Slide 3: Q2 Highlights
Q2 Highlights / Continued positive momentum in Specialty Pharma, Veterinary Services and Diagnostics / A weak quarter in MedTech with underperformance in orthopedics / Strengthened MedTech dental offering through acquisition of AllAccem / Attractive long-term growth prospects in resilient sector Pag
Slide 4: Q2 performance impacted by challenges in MedTech
Q2 performance impacted by challenges in MedTech Revenue and Adj. EBITA Adj EBITA (EURm) Revenue (EURm) x% Adj EBITA margin x% Organic growth (%) Q2 development Net revenue +15% 110 104.9 107.5 104.3 / 15% revenue growth to EUR 104.3m 100 91.3 91.0 28.3 30 87.6 90 82.5 / 5% organic growth impacted b
Slide 5: Specialty Pharma
Specialty Pharma 6% Organic growth / Underlying momentum remains positive with growth across all four therapeutic areas – strongest contribution from Dermatology and Allergy 5% Adj. EBITA growth / Product launches and cross-sales activities are progressing well / Margin improvement driven by operati
Slide 6: MedTech
MedTech -4% Organic growth / Organic decline in MedTech orthopedics in continued soft US surgery market -1% Adj. EBITA decline / Additional actions to strengthen performance - Alireza Tajbakhsh assumes interim operational responsibility for the MedTech segment / Continued strong growth in MedTech de
Slide 7: AllAccem – expanding dental offering
AllAccem – expanding dental offering / Leading provider of dental sealant SANOS® in US / USD 9m in revenues LTM April 2025 / Strong double-digit growth, very high margins / Clinically proven and well-reputed product / Leverage iM3’s commercial infrastructure Page 7
Slide 8: Veterinary Services
Veterinary Services 12% Organic growth / Strong organic growth with continued positive momentum / 9,700 member clinics by end of Q2 16% Adj. EBITA growth / Improved YoY margin driven by revenue growth and positive mix Revenue and Adj. EBITA 20 8 15.4 15.5 16.2 15 14.5 14.3 6 10 5.0 4.7 4 4.4 4.6 4.0
Slide 9: Diagnostics
Diagnostics 18% Organic growth / Continued double-digit organic growth driven by livestock diagnostics offering 32% Adj. EBITA growth / Profitability reflects investments in diversifying the business into companion animal diagnostics market Revenue and Adj. EBITA 5.9 6.0 6 5.7 2.0 4.9 5.0 5 1.5 4 3
Slide 10: Second Quarter Financials
Second Quarter Financials Page 10
Slide 11: Q2 Income Statement
EURm Q2 2025 Q2 2024 Q2 Income Statement April – June April – June Adjusted EBITA 25.4 24.7 / Operating profit (EBIT) EUR 14.5m (13.2) Adjusted EBITA margin (%) 24.3% 27.2% / Items affecting comparability EUR -5.3m (-5.8) Items affecting comparability -5.3 -5.8 • Litigation legal costs in MedTech •
Slide 12: Q2 Cash Flow
EURm Q2 2025 April – June Q2 2024 April – June Q2 Cash Flow EBIT 14.5 13.2 / NWC EUR 99.5m at 25% of revenues per end of June Cash flow from operating activities 30.0 11.6 / Compared to end of March 2025, net working capital increased by EUR before change in NWC 5.2m driven by lower trade payables C
Slide 13: Net Debt and Leverage
Net Debt and Leverage Leverage Net Debt (EUR m) 00 288 285 287 / Net debt per 30 June 2025 EUR 260.6m 80 261 60 / Cash and cash equivalents EUR 67.5m 40 222 20 212 00 / Net Debt / LTM Proforma Adjusted EBITDA 2.1x 80 60 3.0x 2.9x 3.0x 144 140 40 20 2.0x 2.1x 00 1.8x 80 1.3x 60 1.4x 40 20 0 3Q23 4Q23
Slide 14: Concluding remarks from the Chairman of the Board
Concluding remarks from the Chairman of the Board / Leadership changes to drive long-term success implemented – strong interim solution in place / Continuing to execute a robust strategy of profitable organic and acquisition driven growth / Board is confident in Vimian’s ability to deliver on full-y
Slide 15: Q&A
Q&A Page 15